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Abstract
Background:  The antipyretic effectiveness of rectal versus oral acetaminophen is not well
established. This study is designed to compare the antipyretic effectiveness of two rectal
acetaminophen doses (15 mg/kg) and (35 mg/kg), to the standard oral dose of 15 mg/kg.
Methods: This is a randomized, double-dummy, double-blind study of 51 febrile children, receiving
one of three regimens of a single acetaminophen dose: 15 mg/kg orally, 15 mg/kg rectally, or 35 mg/
kg rectally. Rectal temperature was monitored at baseline and hourly for a total of six hours. The
primary outcome of the study, time to maximum antipyresis, and the secondary outcome of time
to temperature reduction by at least 1°C were analyzed by one-way ANOVA. Two-way ANOVA
with repeated measures over time was used to compare the secondary outcome: change in
temperature from baseline at times1, 2, 3, 4, 5, and 6 hours among the three groups. Intent-to-treat
analysis was planned.
Results: No significant differences were found among the three groups in the time to maximum
antipyresis (overall mean = 3.6 hours; 95% CI: 3.2–4.0), time to fever reduction by 1°C or the mean
hourly temperature from baseline to 6 hours following dose administration. Hypothermia
(temperature < 36.5°C) occurred in 11(21.6%) subjects, with the highest proportion being in the
rectal high-dose group.
Conclusion:  Standard (15 mg/kg) oral, (15 mg/kg) rectal, and high-dose (35 mg/kg) rectal
acetaminophen have similar antipyretic effectiveness.
Background
Parents of febrile children often conceive fever as a disease
that requires treatment, rather than being a symptom or a
sign of illness. In their anxious quest to treat fever, parents
suffering from "fever phobia" may end up unintentionally
overdosing their children with different antipyretics, or
with different preparations of the same antipyretic [1-3].
Acetaminophen, in its various preparations, is a widely
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used drug because of its established analgesic and antipy-
retic effects. Whereas the analgesic efficacy achieved with
standard (10–20 mg/kg) oral, standard rectal (10–20 mg/
kg), and high rectal (40–45 mg/kg) acetaminophen doses
have been well investigated [4-7], the comparative antipy-
retic effects of oral and rectal acetaminophen is not well
studied. Parents, as well as physicians, use the standard
dose (10–20 mg/kg) of oral and rectal acetaminophen
preparations interchangeably to treat fever in children,
assuming they have equal antipyretic effects. However,
although the evidence for rapid absorption (within 30–60
minutes) and the pharmacokinetics of a single acetami-
nophen oral dose is well-established [8,9], the pharma-
cokinetics of a single rectal dose reveal the absorption to
be erratic and prolonged, varying with the suppository
size, composition of its base, rate of dissolution, position
in the rectum, and the rectal contents [5]. Moreover, an
increasing body of evidence indicates that the rectal aceta-
minophen dose of 10–15 mg/kg fails to achieve antipy-
retic serum levels of 10–20 µg/ml. Indeed, a rectal
acetaminophen dose of 30–45 mg/kg is needed to achieve
antipyretic serum levels in that range [5,7,10-12].
To our knowledge, only three randomized controlled tri-
als had previously investigated the antipyretic effects of
rectal acetaminophen in comparison to the oral one, with
contradictory results [13-15]. Whereas Leary et al. found
oral paracetamol to be superior to the rectal preparation
in reducing the temperature of febrile children [13], both
Vernon et al [15] and Scolnik et al [14] found no differ-
ence in the antipyretic responses of oral and rectal aceta-
minophen. However, Vernon's study was unblinded and
lacked placebo control, and compared the standard doses
of 15–20 mg/kg of oral and rectal acetaminophen only.
Scolnik's study, also lacking blinding and placebo control,
was further limited by the fact that it assessed antipyresis
during the first three hours after drug administration, a
time during which maximum antipyresis of rectal aceta-
minophen may not have occurred.
In view of the conflicting results in the literature, we con-
ducted this study to compare the antipyretic effectiveness
of two different rectal doses of acetaminophen: 15 mg/kg
and 35 mg/kg to that of a standard oral dose of 15 mg/kg,
over a six-hour period to allow detection of late antipyre-
sis that may occur with rectal acetaminophen. The results
of this study will provide further evidence on the compar-
ative antipyretic effects of different doses of rectal acetami-
nophen versus the standard oral one.
Methods
Setting
This study was conducted between November 2000 and
September 2002, in the paediatric inpatient services of
two hospitals in Beirut: the American University of Beirut
Medical Center (AUBMC), which is a tertiary care facility,
and the Middle East Hospital (MEH), a secondary care
facility. The Institutional Review Board and the Ethics
Committee at the American University of Beirut, as well as
the Board of the Middle East Hospital, approved this
study. Written informed consent was obtained from all
parents as well as the oral consent of children aged 10
years or more.
Subjects
Subjects approached for enrolment in the study were
febrile inpatients whose ages were between 6 months and
13 years, and whose rectal temperature was ≥ 38.5°C. A
wide age range was permitted to enhance recruitment,
since the antipyretic effect of acetaminophen does not
vary with age [9]. Exclusion criteria included any of the
following conditions: acute or chronic gastroenteritis,
vomiting, any medical or surgical condition that pre-
cluded oral or rectal drug administration, acute or chronic
hepatic disease, rectal bleeding, malabsorption syn-
dromes, acute or chronic renal disease with the exception
of urinary tract infection, chronic metabolic disease,
bleeding disorders, chronic neurological disease that may
affect central thermoregulation, cancer, immune suppres-
sion, sepsis, critical medical status, or known allergy to
acetaminophen. Children with concurrent or previous
intake of antibiotics were not excluded. All antipyretics
were stopped for 8 hours prior to the initiation of the
study.
Study design
This is a randomized, double blind, and double dummy
design clinical trial. Subjects were randomized according
to a computer-generated, random-number list that was
kept with the hospital pharmacist until the end of the
study, into one of three treatment groups: standard oral
acetaminophen dose (15 mg/kg) and rectal placebo sup-
positories; standard rectal acetaminophen dose (15 mg/
kg) and oral placebo; high-dose rectal acetaminophen (35
mg/kg) and oral placebo. The allocation sequence was
generated by one of the co-investigators (HT) who was
not involved in subject enrolment or outcome assess-
ment. The pharmacist who prepared the study medica-
tions was aware of subjects' treatment allocation, whereas
subjects, parents, nurses, treating physicians, research
assistant responsible for subject enrolment, data analyst
(co-investigator ZM) and investigators were all blinded to
the assignment of the patients.
Study medications
The drugs used in this study: acetaminophen and its pla-
cebo were supplied by Julphar (Gulf Pharmaceutical
Industries, United Arab Emirates). The oral acetami-
nophen used was a 250 mg acetaminophen/5 ml suspen-
sion (Adol, Julphar), while the placebo was a suspensionBMC Pediatrics 2005, 5:35 http://www.biomedcentral.com/1471-2431/5/35
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with a similar colour and exipient to Adol. The supposito-
ries (Adol) came in three sizes: 125 mg, 250 mg, and 500
mg. The suppository base is lipophyllic and consists of
semi-synthetic glycerides (1140 mg of saturated fatty acids
from C8 to C18). Placebo suppositories consisted of the
same base, and came in similar colour, shape, and sizes.
Study procedure
After obtaining the approval of the treating physician, the
parent(s) of the eligible child was approached for inter-
view and enrolment. During the interview, a trained
research assistant administered a structured questionnaire
designed to collect information on the following varia-
bles: diagnosis, previous or concurrent antibiotics, antipy-
retic intake, fever duration, gender, and date of birth. The
purpose and procedure of the trial were fully explained to
the family, and written parental consent, as well as oral
consent of the subject when older than ten years of age
were obtained. Children enrolled in the study were then
assigned a random number as mentioned previously.
Baseline rectal temperature was recorded using a portable
thermistor with single-use disposable probe covers (Sure
Temp 679, Welch Allyn). One thermometer was used for
the whole duration of the study in each hospital. Investi-
gational drugs were prepared by the pharmacist who was
aware of subjects' treatment allocation as follows: the oral
group would receive oral acetaminophen at a dose of 15
mg/kg through a syringe, followed by placebo rectal sup-
positories which were estimated assuming a rectal aceta-
minophen dose of 35 mg/kg; the second group would
receive oral placebo at a volume similar to the volume
obtained if oral acetaminophen were to be given at a dose
of 15 mg/kg, and rectal suppositories consisting of 15 mg/
kg acetaminophen and 20 mg/kg placebo; the third group
would receive oral placebo, and rectal acetaminophen
suppositories at 35 mg/kg dose. In order to avoid cutting
suppositories, rectal acetaminophen dose was rounded to
the suppository size nearest to the calculated dose. More
than one suppository could be used to achieve the desired
rectal dose. The patient's nurse, who was blinded to the
treatment allocation, administered all drugs and checked
suppository retention for 30 minutes following adminis-
tration and at hourly intervals for the duration of the
study. Rectal temperatures were subsequently recorded at
1, 2, 3, 4, 5, and 6 hours from baseline.
Statistical analyses
The primary outcome was time to maximum antipyresis
following administration of a single dose of acetami-
nophen. Secondary outcomes: included time to fever
reduction by at least 1°C, the temperatures at one, two,
three, four, five, and six hours from administration and
possible side effects such as hypothermia defined as a rec-
tal temperature < 36.5°C.
For sample size calculation, we considered a one-hour dif-
ference in the average time to reach maximum antipyresis
between any of two treatment groups to be a clinically sig-
nificant outcome. Using this one-hour difference to max-
imum antipyresis, a standard deviation of one hour, 80%
power, and alpha of 0.05, the calculated sample size was
48 subjects, 16 in each group.
We used the Chi square test to study the association
between categorical variables and treatment groups, and
one-way ANOVA to investigate the relationship between
continuous variables and treatment groups. Two-way
ANOVA with repeated measures over time was used to
compare the changes in temperature from baseline at each
time (t = 1, 2, ..., 6), among the three groups. Intent-to-
treat analysis was planned with statistical significance set
at P < 0.05.
Results
Baseline characteristics
Between November 2000 and September 2002, 125 par-
ents were approached for interview and questionnaire
administration. The progress of these subjects through the
study is shown in Figure 1. There were no differences in
the baseline characteristics of the patients who completed
the study and those who did not. The study was com-
pleted with 51 subjects: 16 in the oral group, 18 in the rec-
tal standard-dose group, and 17 in the rectal high-dose
group. Their mean (SD) age was 3.9(3.0) years, with an
age range of 6 months-13.1 years. The median duration of
fever was 3.0 days, with a range of 0.5–101.0 days. Three
patients had prolonged fever ranging from 3 weeks to 3
months that were later diagnosed to be due to juvenile
rheumatoid arthritis, central fever, and viral etiology.
These patients were analyzed in their groups since intent
to treat analysis was planned. There were 29 (56.9%)
males, and 35 (68.6%) subjects were receiving at least one
antibiotic when entered into the study.
The characteristics of the three groups are shown in Table
1. There were no significant differences with respect to sex,
age, underlying basic disease causing fever, duration of
fever, previous antipyretic use, or concurrent antibiotic
administration. In addition, there were no differences in
the characteristics or treatment allocation of the patients
recruited from AUBMC (39), and those recruited from
MEH (12). The baseline temperature was similar in the
three groups with a mean (SD) of 39.2 (0.7)°C. As for the
rectal acetaminophen doses, the means (SD) and ranges
were: 14.1 (2.3) mg/kg and 10.7–18.5 mg/kg for the
standard rectal dose; and 31.7 (6.7) mg/kg, and 12.5–43.4
mg/kg for the rectal high-dose respectively. One subject
who was allocated to the rectal high-dose group received
a low rectal dose by mistake. Excluding the dose received
by this patient, the mean (SD) and range for the high-doseBMC Pediatrics 2005, 5:35 http://www.biomedcentral.com/1471-2431/5/35
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rectal group becomes 33.0(4.7) mg/kg and 27.2–43.4 mg/
kg respectively. Since intent-to-treat analysis is planned,
this subject was analyzed in the high-dose group.
Primary outcome
Intent-to-treat analysis of the time to maximum antipyre-
sis, the primary outcome measure of the study, revealed
no significant differences among the three groups (P =
0.5). The overall mean (95% CI) was 3.3 (2.4–4.2) hours
for the rectal low-dose group, 3.6 (2.8–4.3) hours for the
oral group, and 3.9 (3.3–4.6) hours for the rectal high-
dose group [Table 1]. Repeat analysis excluding the three
patients with long duration of fever, and the only patient
who received a low-dose rectal acetaminophen instead of
his allocated high-rectal dose, revealed similar results to
the intent-to-treat analysis. Therefore, analyses of both
primary and secondary outcomes were kept as intent-to-
treat.
Secondary outcomes
The mean (95%CI) maximum decline in temperature was
1.6(1.3–2.0)°C in the rectal low-dose group, 1.7(1.2–
2.2)°C in the oral group, and 2.0(1.4–2.5)°C in the rectal
high-dose group (P = 0.5). The time to fever reduction by
at least 1°C was similar among the three groups: mean
(95% CI) of 2.4 (1.8–3.1) hours in the rectal low-dose,
3.5 (2.6–4.4) hours in the oral and 2.8 (2.1–3.6) hours in
the rectal high-dose groups (P = 0.13). Two-way ANOVA
with repeated measures over time did not reveal statisti-
cally significant differences in the changes in temperature
from baseline at times 1, 2, ..., 6 hours among the three
groups (P = 0.25).
As for side effects of the medications, hypothermia,
defined as a body temperature below 36.5°C rectally,
occurred in 11 (21.6%) subjects: 2(11.1%) with the rectal
standard dose, 3(18.8%) in the oral group and 6(35.3%)
with the rectal high-dose. These proportions however
were not statistically significant (P = 0.2). The temperature
range of hypothermic episodes was between 35.5°C and
36.4°C (mean 36.1°C).
There were three mortalities among our subjects, which
were judged to be unrelated to the investigational drugs.
The first one was a one-year-old male infant who died 10
days after enrolment from systemic Epstein-Barr viral
infection. The second mortality occurred in a 12-year-old
child who succumbed to bacterial endocarditis and myo-
cardial abscesses two weeks following enrolment in the
study, and the third patient was a six month old boy
whose clinical status deteriorated four hours after enrol-
ment, the time at which he was withdrawn from the study.
This patient died 14 hours later from complicated respira-
tory infection, sepsis, and respiratory failure.
Discussion
Acetaminophen is the most widely used antipyretic in
paediatric medicine. Despite the well-established antipy-
retic effects of oral and rectal acetaminophen, controversy
regarding the comparative antipyretic effectiveness of the
two types of acetaminophen preparations is yet unre-
solved. Whereas some investigators have reported better
antipyresis with oral acetaminophen [13], others have
reported equal antipyretic effects [14,15]. Faced with this
uncertainty, the use of either preparation is often influ-
enced by the child's acceptance of the oral medication, his
medical condition (presence of vomiting for example),
and parental or physician preferences.
Our results reveal no difference in the antipyretic effective-
ness among oral, rectal standard-dose, or rectal high-dose
acetaminophen. The time to maximum antipyresis was
not significantly different among the three doses or prep-
arations of the drug, with an overall mean (SD) of
3.3(95%CI: 2.4–4.2) hours. In addition, the three regi-
mens behaved similarly with respect to the maximum
decline in temperature at any time during the six hours
and the time to fever reduction by at least one degree. Our
findings are in agreement with those of Vernon, et al [15]
and Scolnik, et al [14], but different from those of Leary et
al [13]. These differences may be attributed to the fact that
in Leary's study, all outcome measurements were based
Flow diagram of the subjects' progress through the study Figure 1
Flow diagram of the subjects' progress through the study.BMC Pediatrics 2005, 5:35 http://www.biomedcentral.com/1471-2431/5/35
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on axillary temperatures, the reliability of which is uncer-
tain [16].
This study is the fourth randomized controlled trial that
compares the antipyretic effectiveness of oral and rectal
acetaminophen, and the second one to investigate the dif-
ferences in antipyresis between standard oral, standard
rectal, and high-dose rectal acetaminophen. The strengths
of this study, as compared to the previous ones, include
the fact that the six-hour study duration permitted detec-
tion of any delayed antipyretic responses, if present. In
addition, it was double-blinded with double-dummy
technique. In contrast, the study of Scolnik et al [14]
assessed antipyresis for the first three hours only, the time
at which maximum antipyresis may not have occurred. In
addition, it was neither blinded, nor placebo-controlled.
Similarly, Vernon et al's study [15] lacked both blinding
and placebo control, and compared the standard doses of
15–20 mg/kg of oral and rectal acetaminophen only.
Finally, the main drawback of Leary et al's study [13] was
Table 1: Subject characteristics and main outcome.
TOTAL RECTAL (15 MG/KG) ORAL (15 MG/KG) RECTAL (35 MG/KG)
Total 51 18 16 17
Male Gender
N (%) 29 (56.9) 11 8 10
Age (years):
Mean (SD) 4.1 (3.5) 3.8 (2.8) 4.0 (3.6) 3.5 (3.0)
Range 0.5–13.1 0.6–13.1 0.5–10.2 0.5–12.4
Diagnosis:¶ N (%)
Pneumonia 10 (19.6) 3 2 5
UTI 7 (13.7) 2 4 1
Virus 17 (33.3) 6 4 7
Bacteremia 5 (9.8) 2 2 1
Others 36 (70.5) 15 12 9
Previous antipyretic 
N (%)
Acetaminophen 40(78.4) 15 14 11
Ibuprofen 8(15.6) 2 2 4
Antibiotic intake 
N (%) 35 (68.6) 16 8 11
Acetaminophen Dose (mg/kg):
Mean (SD) § 14.1(2.3) 15.0(0.0) 31.7(6.7)
Range 10.7–18.5 15.0–15.0 12.5–43.4
Duration of fever (days):
Median 3.0 3 1.3 5
Range 0.5–101.0 1.0–90.0 0.5–15.0 1.0–101.0
Baseline temperature
Mean (SD) 39.2 (0.7) 39.1 (0.9) 39.3 (0.6) 39.1 (0.6)
Time to max AP in hr:
Mean 3.6 3.3 3.6 3.9
95% CI 3.2–4.0 2.4–4.2 2.8–4.3 3.3–4.6
§ P = 0.000 (ANOVA); ¶ Percentages do not add up to 100 since more than one diagnosis is entered for some subjects; max AP: maximum 
antipyresis; hr: hour.BMC Pediatrics 2005, 5:35 http://www.biomedcentral.com/1471-2431/5/35
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their use of axillary temperature instead of the gold stand-
ard rectal measurements, which undermines the reliabil-
ity of their results.
Our study is limited by the fact that it included inpatients
only, the majority of which were on antibiotics and had
previously received antipyretics. However, our findings
can be generalized to febrile children who are treated as
outpatients, since the antipyretic response to acetami-
nophen is not known to vary between inpatients and out-
patients. In addition, and since our outcome of interest is
"effectiveness" rather than "efficacy", we did not exclude
subjects receiving antibiotics from enrolment nor subjects
with prior intake of antipyretics. Antipyretics however
were stopped for 8 hours prior to enrolment, the time at
which a febrile subject may receive antipyretic treatment
in "real clinical life". It may be argued that the antipyretic
effects of the investigational drugs are confounded by
antibiotic administration and previous antipyretic intake.
However since this is a randomized clinical trial, we antic-
ipated that the randomization process will dilute these
effects by distributing these subjects equally among the
three treatment groups. Indeed, the proportions of sub-
jects receiving antibiotics and those with prior antipyretic
intake were not significantly different among the three
groups, suggesting adequate randomization. A weakness
of this study is the inter-individual variability of the aceta-
minophen dose in the rectal high-dose group which
ranged between 27.2 and 43.4 mg/kg, after exclusion of
the subject who received a low dose by mistake. It is pos-
sible that the lower acetaminophen doses in this range
may have attenuated the mean antipyretic effect of this
group resulting in similar antipyretic responses among the
three different groups. This problem however is difficult
to avoid with rectal administration and is frequently
encountered in real clinical life. We cannot therefore elim-
inate the possibility of some imprecision of the results in
the rectal high-dose group due to dosage variability.
It is interesting to note that one fifth of our patients devel-
oped hypothermia during the study interval, a finding
that has not been previously reported. Though the differ-
ences in the proportions of patients with hypothermia
among the three groups did not achieve statistical signifi-
cance, the rectal high-dose group tended to have a higher
proportion with hypothermia. This observation needs to
be further investigated with a larger sample size, since our
study was not powered to detect whether hypothermia is
more common in one group as compared to the others.
Conclusion
In conclusion, oral and rectal acetaminophen prepara-
tions seem to have equal antipyretic effectiveness which is
in line with earlier studies. There is no evidence to support
the belief that rectal suppositories, whether prescribed in
the standard dose of 15 mg/kg, or in the high dose of 30–
40 mg/kg, are superior to oral acetaminophen in terms of
rapidity of action, or in the extent of temperature reduc-
tion. Though the oral route may be preferred because of its
predictable rapid absorption, the rectal route seems to be
a good and equally effective alternative in special circum-
stances like vomiting, or conditions preventing oral
administration. High-dose rectal acetaminophen should
be used with caution, since it may result in hypothermia,
a finding that deserves further exploration in the future.
Physicians should educate parents about fever being a
benign symptom of illness, rather than a disease in itself.
While it is desirable to treat fever in children, parents need
to be aware that fever per se is not a usual cause of mortal-
ity in a child, while acetaminophen overdose can be [1-3].
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